Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TransMedics (TMDX) Operating Expenses (2018 - 2026)

TransMedics has reported Operating Expenses over the past 8 years, most recently at $72.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 13.84% year-over-year to $72.1 million; the TTM value through Dec 2025 reached $254.2 million, up 13.2%, while the annual FY2025 figure was $254.2 million, 13.2% up from the prior year.
  • Operating Expenses for Q4 2025 was $72.1 million at TransMedics, up from $61.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $72.1 million in Q4 2025 and troughed at $11.3 million in Q1 2021.
  • A 5-year average of $40.9 million and a median of $41.5 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: skyrocketed 191.63% in 2023 and later dropped 17.5% in 2024.
  • Year by year, Operating Expenses stood at $18.3 million in 2021, then skyrocketed by 50.06% to $27.5 million in 2022, then surged by 64.91% to $45.3 million in 2023, then soared by 39.82% to $63.4 million in 2024, then rose by 13.84% to $72.1 million in 2025.
  • Business Quant data shows Operating Expenses for TMDX at $72.1 million in Q4 2025, $61.3 million in Q3 2025, and $60.0 million in Q2 2025.